Welcome back to Stockhouse
Member Sign In

Email or Username:

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

Telesta Therapeutics Inc. T.TST

Sector: Healthcare | Sub-Sector: Biotechnology
Alternate Symbol(s):  BNHLF

Telesta Therapeutics Inc is a human therapeutics company. The Company is engaged in the manufacturing, marketing and licensing/acquisition of proprietary therapies for the global human health market.
Price: $0.305 | Change: +$0.005 | %Change: +1.67%
Volume: 268,994 | Day High/Low: 0.31/0.29 | 52 Week High/Low: 0.435/0.14
View modes: 
0 stars


Cant you put your sht to rhyme rapperboy.  It would be more tolerable than the same ole-bich  rate and reply
0 stars

Obama boy

keep tellin ya.......ya got to fill a pocket or two says his salary is contractually underwritten in part by several large pharmaceutical companies, including Merck, Bristol-Myers Squibb, Eli more
0 stars


ENDO WALKED..........  rate and reply
0 stars


Let's all see how slow they all can move this week.    God forbid CANCER was ever a time sensitive issue.....   Fire up your NEURONS smarty-pants.    You're still useless  rate and reply
0 stars

Lilly's new insulin is likely DOA after latest delay, analyst says February 23, 2015 | By Damian Garde  rate and reply
0 stars

RE:Safety is the key

A bottle of sulfuric has less warnings  rate and reply
0 stars

RE:RE:The difference between you and me...

Where the F is DimDum?   His stupidity was the major reason I stayed on here.   And to give him enough material to print off his printer.  Haha.  What a loser  rate and reply
0 stars

RE:The difference between you and me...

What insults and depresses me is that it takes educated people too long to help the sick because some human mind somewhere thinks that there is a chance to make "money" from the treatment. more
0 stars

The difference between you and me...

Is that I DONT CARE when the stock "hits", because I'm giving all of the money away anyways.    While you people try and make some pesos to buy a new car.   Good luck.  rate and reply
0 stars

Safety is the key

Pfizer Inc.: Working together for a healthier world® Priority review.... RAPAMUNE Important Safety Information There is an increased risk of developing infections or certain cancers, more
0 stars

RE:RE:RE:RE:one missing item on website

Great post Rube. Potential partners would run those numbers 6 ways from Sunday and would understand that. I guess I was more hoping the investment public would starts to grasp what the numbers more
0 stars

Bladder cancer patients

Your government has failed you miserably.   My thoughts and prayers are with you and your families while these gorillas look at making money before they make you well.   Your well being is more
5 stars

RE:RE:RE:one missing item on website

I agree with the efficacy data Beech is quoting.  However, I am am reluctant to fault TST management for not promoting it aggressively.  It may be a smart strategy on their part. The reason has to more
0 stars

RE:Never Ending

Wast'in time dealing with the PC's....Solidarity Fund QFL buyin in is the way to go....If things don't pan out they can always sell their shares to huey & duey  rate and reply
0 stars

Never Ending

Who is lobbying? Bioniche Life Sciences Inc. Responsible Officer Name Michael Berendt, CEO Grant, Contribution or Other Financial Benefit Urocidin plant expansion project relating to the more
1.5 stars

RE:RE:one missing item on website

. Who is this shareholder presentation intended for? Maybe trying to suck these guys in again..........Updated April 22, 2013 at 16h19 The Solidarity Fund QFL has lost nearly $ 7 million in more
5 stars

RE:RE:one missing item on website

the trial was with both papillary and carsinoma in situ. Carcinoma in situ (the harder to treat poplulation) was 20% CRR, the more prevalent Papillary (90% of refractory bladder cancers) had a CRR more
1 star

RE:one missing item on website

beach guy where do you get the 35 and 50% figures from? Neither of these DF rates are evident in the Urology Journal trial review that is on the website ( the one that apparently no one has read). more
2.5 stars

RE:one missing item on website

You mean they stiill cant get it together on the webpage?   PS Be carefully of the beechifier.  While TST is a very good bet, it is still a bet.  A bet that can be beset by delays, major more
5 stars

one missing item on website

I wish somewhere they would put that they had a CRR of over 35% on Pappilary. Carcinoma InSitu was 20%, but that is only 10% of the population base, whereas 90% are Pappilary. That means over a more